Cited by 105Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsCurcumin's Biomedical Applications

Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer’s Disease

Open access
Sundaram, Jeyapriya Raja, Poore, Charlene Priscilla, Sulaimee, Noor Hazim Bin, Pareek, Tej, Cheong, Wei Fun, Wenk, Markus R., Pant, Harish C., Frautschy, Sally A. +2 more·2017·Journal of Alzheimer s Disease

Abstract

Several studies have indicated that neuroinflammation is indeed associated with neurodegenerative disease pathology. However, failures of recent clinical trials of anti-inflammatory agents in neurodegenerative disorders have emphasized the need to better understand the complexity of the neuroinflammatory process in order to unravel its link with neurodegeneration. Deregulation of Cyclin-dependent kinase 5 (Cdk5) activity by production of its hyperactivator p25 is involved in the formation of tau and amyloid pathology reminiscent of Alzheimer's disease (AD). Recent studies show an association between p25/Cdk5 hyperactivation and robust neuroinflammation. In addition, we recently reported the novel link between the p25/Cdk5 hyperactivation-induced inflammatory responses and neurodegenerative changes using a transgenic mouse that overexpresses p25 (p25Tg). In this study, we aimed to understand the effects of early intervention with a potent natural anti-inflammatory agent, curcumin, on p25-mediated neuroinflammation and the progression of neurodegeneration in p25Tg mice. The results from this study showed that curcumin effectively counteracted the p25-mediated glial activation and pro-inflammatory chemokines/cytokines production in p25Tg mice. Moreover, this curcumin-mediated suppression of neuroinflammation reduced the progression of p25-induced tau/amyloid pathology and in turn ameliorated the p25-induced cognitive impairments. It is widely acknowledged that to treat AD, one must target the early-stage of pathological changes to protect neurons from irreversible damage. In line with this, our results demonstrated that early intervention of inflammation could reduce the progression of AD-like pathological outcomes. Moreover, our data provide a rationale for the potential use of curcuminoids in the treatment of inflammation associated neurodegenerative diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-170093

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 62 · Cited by 105

Authors
Sundaram, J. R., Poore, C. P., Sulaimee, N. H. B., Pareek, T., Cheong, W. F., Wenk, M. R., Pant, H. C., Frautschy, S. A., Low, C.-M., & Kesavapany, S.
Affiliations
  • National University of Singapore (SG)
  • Case Western Reserve University (US)
  • National Institutes of Health (US)
  • University of California, Los Angeles (US)
Corresponding author
Kesavapany, Sashi
Venue
Journal of Alzheimer s Disease
Published
2017-11-07
Volume
60
Issue
4
Pages
1429-1442
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2761591067
Cited by
105
References
62
Citations by year
2026: 8 · 2025: 12 · 2024: 14 · 2023: 12 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 9 · 2018: 6
FWCI
6.27
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • National University of Singapore (submittedVersion)
Funders
  • U.S. Department of Veterans Affairs (I01 RX000669, I01 BX001257, I01 BX003485, I01 BX000542)
  • National Institute on Aging (R21AG050269)
  • National Center for Complementary and Integrative Health (R01AT006816)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
Keywords
curcumin, neuroinflammation
MeSH terms
Alzheimer Disease, Animals, Anti-Inflammatory Agents, Astrocytes, Brain, Curcumin, Humans, Inflammation, Memory Disorders, Mice, Inbred CBA, Mice, Inbred C57BL, Mice, Transgenic, Nerve Degeneration, Neuroimmunomodulation, Neuroprotective Agents, Nootropic Agents, Calcium-Calmodulin-Dependent Protein Kinase Type 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review